Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC

Background & Aims: Fibroblast growth factor 21 (FGF21) is a crucial regulator of cell metabolism. Tumour-secreted FGF21 has shown immune-checkpoint factor functions, and high FGF21 levels are associated with a poor prognosis for patients. However, its prognostic value and impact on treatment res...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Risako Kohya, Goki Suda, Masatsugu Ohara, Shunichi Hosoda, Takuya Sho, Makoto Chuma, Atsumasa Komori, Yuki Kugiyama, Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Joji Tani, Shun Kaneko, Mina Nakagawa, Yasuhiro Asahina, Shinya Maekawa, Nobuyuki Enomoto, Yoshiya Yamamoto, Masaru Baba, Ren Yamada, Takashi Sasaki, Tomoka Yoda, Sonoe Yoshida, Qingjie Fu, Zijian Yang, Osamu Maehara, Shunsuke Ohnishi, Yoshimasa Tokuchi, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Mitsuteru Natsuizaka, Koji Ogawa, Naoya Sakamoto
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-05-01
Edice:	JHEP Reports
Témata:	FGF21 Atezolizumab Bevacizumab Hepatocellular Carcinoma Immune-checkpoint inhibitor Prognosis
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589555925000412
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!